Innoviva, Inc. (INVA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 12.96 |
| Open | 12.95 |
| Bid | 12.58 x 1200 |
| Ask | 13.02 x 1000 |
| Day's Range | 12.74 - 13.10 |
| 52 Week Range | 11.57 - 20.71 |
| Volume | |
| Avg. Volume | 624,181 |
| Market Cap | 893.225M |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 5.64 |
| EPS (TTM) | 2.27 |
| Earnings Date | Feb 07, 2023 - Feb 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Sep 08, 2015 |
| 1y Target Est | 17.50 |
- Insider Monkey
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […]
- PR Newswire
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross p
- Zacks
Innoviva (INVA) Gains As Market Dips: What You Should Know
In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.
